

Abbreviations

ACEi	Angiotensin Converting Enzyme inhibitors
AF	Atrial fibrillation
ARBs	Angiotensin Receptor Blockers
AV	Atrio-Ventricular
AVN	Atrio-Ventricular Node
BAD	Pro-Apoptotic Molecule.
BiV	Bi-Ventricular
BMI	Body Mass Index
CABG	Coronary Artery Bypass Grafting
CKD	Chronic Kidney Disease
COPD	Chronic Obstructive Pulmonary Disease
CRT	Cardiac Resynchronization Therapy
CRT-P	CRT-Pacemaker
CRT-D	CRT-Defibrillator
CS	Coronary Sinus
cTVI	color-coded Tissue Velocity Imaging
DCM	Dilated CardioMyopathy
DM	Diabetes Mellitus
dp/dt	difference in pressure/time
ECG	ElectroCardioGram
eGFR	estimated Glumerular filtration rate
ERK	Extracellular Receptor Kinase
FT/RR	filling time (FT) /cardiac cycle length (RR)
Hb	Hemoglobin
HF	Heart Failure
HTN	arterial Hypertension
ICD	Internal Cardioverter Defibrillator
ICM	Ischemic Cardiomyopathy
IEGM	Intracardiac ElectroGraM
IO	Intra-Operative
IVCD	Inter-Ventricular Conduction Delay
IVD	InterVentricular Delay
LBBB	Left Bundle Branch Block
LAO	Left anterior Oblique
LV	Left Ventricular
LVEF	Left Ventricular Ejection Fraction
LVEDV	Left ventricular End Diastolic Volume
LVESV	Left ventricular End Systolic Volume

LVAD	Left Ventricular Assist device
LVIDd	Left Ventricular Internal Dimension at end diastole
LVIDS	Left Ventricular Internal Dimension at end systole
LPVEI	Left Ventricular Pre-Ejection Interval
M	Meter
MAP	Mitogen-Activated protein
MHC	Myosin Heavy Chain
MPI	Myocardial Performance index
MR	Mitral Regurgitation
MRA	Mineralocorticoid Receptor Antagonists
MRI	Magnetic resonance imaging
MVO2	Maximal / Myocardial Oxygen consumption
N	Number
N-ICM	Non-ischemic CardioMyopathy
NYHA	New York Heart Association
PCI	Percutaneous coronary intervention
PHT	Pulmonary HyperTension
PLB	Phospholamban
Qol	Quality of Life
QRSd	QRS duration
RAAS	Renin-Angiotensin-Aldosterone-System
RAO	Right Anterior Oblique
RBBB	Right Bundle Branch Block
RVd	Right Ventricular dimension
SERCA	SarcoEndoplasmic Reticulum Calcium ATPase
SMV	Systolic Maximal Velocity
SN	Sinus Node
SPWMD	Septal-Posterior Wall Motion Delay
SR	Sinus Rhythm
TAPSE	Tricuspid Annular Peak systolic Excursion
TNF- α	Tumor Necrosis Factor- α
Ts-sep-lat	Peak systolic velocity delay in ejection phase at basal septal and lateral segments
TPG	Trans-Pulmonary gradient
TVI	Tissue Velocity imaging
VTIao	Velocity Time Integral at aortic valve
VV	Ventriculo-Ventricular (interventricular)
3D	3-Dimensional
6.MWD	6 minute Walk Distance

List of Tables

Table 1.1	Table 1.1: Indications for CRT.
Table 1.2	Nonresponders to resynchronization therapy: Potential etiologies.
Table 3.1	Baseline characteristics; clinical data.
Table 3.2	Baseline characteristics; ECG.
Table 3.3	Baseline characteristics; echocardiography.
Table 3.4	LV lead position.
Table 3.5	Effects of CRT; echocardiography.
Table 3.6	Effect of CRT on clinical status and renal function.
Table 3.7	Responders vs. non-responders baseline characteristics.
Table 3.8	Responders vs. non-responders baseline baseline characteristic and events.
Table 3.9	Baseline NYHA and response.
Table 3.10	Co-morbid conditions and CRT response.
Table 3.11	ECG and response.
Table 3.12	Echocardiography and CRT response.
Table 3.13	Etiology and revascularization vs CRT response.
Table 3.14	LV lead position and CRT response.
Table 3.15	Points in the CRTscore.
Table 3.16	CRT response according to the CRTscore.
Table 3.17	CRT response in patients with CRTscore ≥ 6 .
Table 3.18	CRTscore and response in patients with class I indication.
Table 3.19	CRTscore and response in patients with class IIa indication.
Table 3.20	CRTscore and response in patients with class IIb/III indication.
Table 4.1	Baseline characteristics in different studies.

List of Figures

Figure 1.1	Treatment options for patients with chronic symptomatic systolic heart failure
Figure 1.2	Color-coded electroanatomic isochronal ventricular activation in a heart failure patient with left bundle branch block.
Figure 1.3	Cardiac dyssynchrony and circumferential strain, stiffening, pressure–volume relation and Stress-strain loops.
Figure 1.4	M-mode imaging; septal to posterior wall mechanical delay.
Figure 1.5	Color-coded Tissue Doppler Imaging.
Figure 1.6	Speckle Tracking Imaging. Regional radial strain is displayed over time.
Figure 1.7	Acute effects of CRT.
Figure 1.8	Effect of resynchronization therapy on 6-minute walk distance, MVO ₂ max, and Quality of Life.
Figure 1.9	Effect of resynchronization therapy on LV ejection fraction.
Figure 1.10	The cardiac venous system.
Figure 1.11	Fluoroscopy: lateral side branch draining in the middle cardiac vein.
Figure 1.12	Different anchoring mechanisms of available LV-pacing leads.
Figure 1.13	Electrical reprogramming to avoid phrenic nerve stimulation.
Figure 1.14	Position of LV lead in a lateral vein.
Figure 2.1	Angiographic classification of left ventricular lead position.
Figure 3.1	Example LV lead position in basal lateral wall.
Figure 3.2	Gender difference in response.
Figure 3.3	Renal disease and CRT response.
Figure 3.4	COPD and CRT response.
Figure 3.5	QRS duration and response.
Figure 3.6	QRS morphology and response.
Figure 3.7	Rhythm at CRT implantation and CRT response.
Figure 3.8	Etiology and CRT response.
Figure 3.9	LV lead position and CRT response.
Figure 3.10	Magnitude of benefit from CRT.
Figure 3.11	CRT response according to the CRTscore.
Figure 3.12	CRT response in patients with CRTscore ≥ 6 .
Figure 3.13	CRTscore and response in patients with class I indication.
Figure 3.14	CRTscore and response in patients with class IIa indication.
Figure 3.15	CRTscore and response in patients with class IIb/III indication.
Figure 3.16	Guidelines and CRT response.
Figure 3.17	Guidelines, CRTscore and CRT response